Seminars in Ultrasound, CT and MRI
Volume 30, Issue 4 , Pages 326-351 , August 2009

Magnetic Resonance Imaging of Renal Masses

  • Maryellen R.M. Sun, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Maryellen R.M. Sun, MD, Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215
    • ,
  • Ivan Pedrosa, MD

References 

  1. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203–205
  2. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: Study of 1092 patients (1982-1997). Urology. 2000;56:58–62
  3. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  4. Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol. 2006;33:534–543
  5. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601–5608
  6. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007;13:764s–769s
  7. Pedrosa I, Chou MT, Ngo L, et al. MR classification of renal masses with pathologic correlation. Eur Radiol. 2008;18:365–375
  8. Ng CS, Wood CG, Silverman PM, et al. Renal cell carcinoma: Diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008;191:1220–1232
  9. Rofsky NM, Weinreb JC, Bosniak MA, et al. Renal lesion characterization with gadolinium-enhanced MR imaging: Efficacy and safety in patients with renal insufficiency. Radiology. 1991;180:85–89
  10. Perez-Rodriguez J, Lai S, Ehst B, et al. Nephrogenic systemic fibrosis: Incidence, associations, and effect of risk factor assessment—report of 33 cases. Radiology. 2009;250:371–377
  11. Prince M, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807–816
  12. Pedrosa I, Sun MR, Spencer M, et al. MR imaging of renal masses: Correlation with findings at surgery and pathologic analysis. RadioGraphics. 2008;28:985–1003
  13. Zhang J, Pedrosa I, Rofsky NM. MR techniques for renal imaging. Radiol Clin North Am. 2003;41:877–907
  14. Nolte-Ernsting CC, Bucker A, Adam GB, et al. Gadolinium-enhanced excretory MR urography after low-dose diuretic injection: Comparison with conventional excretory urography. Radiology. 1998;209:147–157
  15. Ehman RL, Felmlee JP. Adaptive technique for high-definition MR imaging of moving structures. Radiology. 1989;173:255–263
  16. Israel GM, Hindman N, Hecht E, et al. The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas. AJR Am J Roentgenol. 2005;184:1868–1872
  17. Earls JP, Rofsky NM, DeCorato DR, et al. Breath-hold single-dose gadolinium-enhanced three-dimensional MR aortography: Usefulness of a timing examination and MR power injector. Radiology. 1996;201:705–710
  18. Earls JP, Rofsky NM, DeCorato DR, et al. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: Optimization with a test examination and a power injector. Radiology. 1997;202:268–273
  19. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. Eur J Radiol. 2008;66:230–234
  20. Saxena SK, Sharma M, Patel M, et al. Nephrogenic systemic fibrosis: An emerging entity. Int Urol Nephrol. 2008;40:715–724
  21. Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin North Am. 2008;16:551–560vii
  22. Williams DS, Detre JA, Leigh JS, et al. Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci USA. 1992;89:212–216
  23. De Bazelaire C, Rofsky NM, Duhamel G, et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma. Acad Radiol. 2005;1:347–357
  24. de Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:5548–5554
  25. Pedrosa I, Robson P, Smith MP, et al. Characterization of renal masses with arterial spin labeling MRI in patients with impaired renal function in the era of nephrogenic systemic fibrosis. Toronto, Canada: Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM); 2008;
  26. Manenti G, Di RM, Mancino S, et al. Malignant renal neoplasms: Correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med. 2008;113:199–213
  27. Cova M, Squillaci E, Stacul F, et al. Diffusion-weighted MRI in the evaluation of renal lesions: Preliminary results. Br J Radiol. 2004;77:851–857
  28. Squillaci E, Manenti G, Cova M, et al. Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res. 2004;24:4175–4179
  29. Squillaci E, Manenti G, Di Stefano F, et al. Diffusion-weighted MR imaging in the evaluation of renal tumours. J Exp Clin Cancer Res. 2004;23:39–45
  30. Bostwick DG, Eble JN. Diagnosis and classification of renal cell carcinoma. Urol Clin North Am. 1999;26:627–635
  31. Bostwick DG, Murphy GP. Diagnosis and prognosis of renal cell carcinoma: Highlights from an international consensus workshop. Semin Urol Oncol. 1998;16:46–52
  32. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–624
  33. Novara G, Martignoni G, Artibani W, et al. Grading systems in renal cell carcinoma. J Urol. 2007;177:430–436
  34. Scialpi M, Di Maggio A, Midiri M, et al. Small renal masses: Assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression. AJR Am J Roentgenol. 2000;175:751–757
  35. Sun MR, Ngo L, Genega EM, et al. Renal cell carcinoma: Dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes—Correlation with pathologic findings. Radiology. 2009;250:793–802
  36. Breen EC. VEGF in biological control. J Cell Biochem. 2007;102:1358–1367
  37. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the Von Hippel–Lindau gene mutation. Cancer Res. 2002;62:2957–2961
  38. Bissada NK, Yakout HH, Babanouri A, et al. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology. 2003;61:89–92
  39. Leroy X, Zini L, Leteurtre E, et al. Morphologic subtyping of papillary renal cell carcinoma: Correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol. 2002;15:1126–1130
  40. Garin JM, Marco I, Salva A, et al. CT and MRI in fat-containing papillary renal cell carcinoma. Br J Radiol. 2007;80:e193–e195
  41. Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: Meaning of histological typing and multifocality. J Urol. 2003;170:764–767
  42. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: Clinicopathological features of 50 cases. J Urol. 1995;154:964–967
  43. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875
  44. Kondo T, Nakazawa H, Sakai F, et al. Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: A retrospective analysis on computed tomography and magnetic resonance imaging studies. Int J Urol. 2004;11:817–824
  45. Pickhardt PJ, Lonergan GJ, Davis CJ, et al. From the archives of the AFIP (Infiltrative renal lesions: radiologic-pathologic correlation. Armed Forces Institute of Pathology). Radiographics. 2000;20:215–243
  46. Halat SK, MacLennan GT. Multilocular cystic renal cell carcinoma. J Urol. 2007;177:343
  47. Prasad SR, Humphrey PA, Catena JR, et al. Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation. RadioGraphics. 2006;26:1795–1806discussion, 1806-1710
  48. Karakiewicz PI, Hutterer GC, Trinh QD, et al. Unclassified renal cell carcinoma: An analysis of 85 cases. BJU Int. 2007;100:802–808
  49. Davidson AJ, Choyke PL, Hartman DS, et al. Renal medullary carcinoma associated with sickle cell trait: Radiologic findings. Radiology. 1995;195:83–85
  50. Nocks BN, Heney NM, Daly JJ, et al. Transitional cell carcinoma of renal pelvis. Urology. 1982;19:472–477
  51. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: A review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15:127–139
  52. Browne RF, Meehan CP, Colville J, et al. Transitional cell carcinoma of the upper urinary tract: Spectrum of imaging findings. RadioGraphics. 2005;25:1609–1627
  53. Pedrosa I, Rofsky N. The kidney. In:  Edelman RR,  Hesselink RR,  Zlatkin MB, et al. editor. Clinical Magnetic Resonance Imaging. (ed 3). Philadelphia, PA: Elsevier; 2006;
  54. Adey GS, Genega EM, Pedrosa I, et al. Upper urinary tract carcinoma: Transitional or renal cell?. Issues Urol. 2006;18:234–238
  55. Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98:1620–1626
  56. Blacher EJ, Johnson DE, Abdul-Karim FW, et al. Squamous cell carcinoma of renal pelvis. Urology. 1985;25:124–126
  57. Hartman DS, David CJ, Goldman SM, et al. Renal lymphoma: Radiologic-pathologic correlation of 21 cases. Radiology. 1982;144:759–766
  58. Urban BA, Fishman EK. Renal lymphoma: CT patterns with emphasis on helical CT. RadioGraphics. 2000;20:197–212
  59. Semelka RC, Kelekis NL, Burdeny DA, et al. Renal lymphoma: Demonstration by MR imaging. AJR Am J Roentgenol. 1996;166:823–827
  60. Lebowitz JA, Rofsky NM, Weinreb JC, et al. Ureteral lymphoma: MRI demonstration. Abdom Imaging. 1995;20:173–175
  61. Bailey JE, Roubidoux MA, Dunnick NR. Secondary renal neoplasms. Abdom Imaging. 1998;23:266–274
  62. Nikken JJ, Krestin GP. Magnetic resonance in the diagnosis of renal masses. BJU Int. 2000;86:58–69(suppl 1)
  63. Wagner BJ, Wong-You-Cheong JJ, Davis CJ. Adult renal hamartomas. RadioGraphics. 1997;17:155–169
  64. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: Abdominopelvic CT and US findings. Radiology. 2000;216:147–153
  65. Wills JS. Management of small renal neoplasms and angiomyolipoma: A growing problem. Radiology. 1995;197:583–586
  66. Bosniak MA, Megibow AJ, Hulnick DH, et al. Diagnosis of renal angiomyolipoma: The importance of detecting small amounts of fat. AJR Am J Roentgenol. 1988;151:497–501
  67. Silverman SG, Gan YU, Mortele KJ, et al. Renal masses in the adult patient: The role of percutaneous biopsy. Radiology. 2006;240:6–22
  68. Agrawal R, Jafri SZ, Gibson DP, et al. Juxtaglomerular cell tumor: MR findings. J Comput Assist Tomogr. 1995;19:140–142
  69. Kashiwabara H, Inaba M, Itabashi A, et al. A case of renin-producing juxtaglomerular tumor: Effect of ACE inhibitor or angiotensin II receptor antagonist. Blood Press. 1997;6:147–153
  70. Amin MB, Crotty TB, Tickoo SK, et al. Renal oncocytoma: A reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol. 1997;21:1–12
  71. Kuroda N, Toi M, Hiroi M, et al. Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18:935–942
  72. Harmon WJ, King BF, Lieber MM. Renal oncocytoma: Magnetic resonance imaging characteristics. J Urol. 1996;155:863–867
  73. Pretorius ES, Siegelman ES, Ramchandani P, et al. Renal neoplasms amenable to partial nephrectomy: MR imaging. Radiology. 1999;212:28–34
  74. Ball DS, Friedman AC, Hartman DS, et al. Scar sign of renal oncocytoma: Magnetic resonance imaging appearance and lack of specificity. Urol Radiol. 1986;8:46–48
  75. Gelb AB, Simmons ML, Weidner N. Solitary fibrous tumor involving the renal capsule. Am J Surg Pathol. 1996;20:1288–1295
  76. Johnson TR, Pedrosa I, Goldsmith J, et al. Magnetic resonance imaging findings in solitary fibrous tumor of the kidney. J Comput Assist Tomogr. 2005;29:481–483
  77. Madewell JE, Goldman SM, Davis CJ, et al. Multilocular cystic nephroma: A radiographic-pathologic correlation of 58 patients. Radiology. 1983;146:309–321
  78. Adey GS, Pedrosa I, Rofsky NM, et al. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. Urology. 2008;71:47–51
  79. Kettritz U, Semelka RC, Siegelman ES, et al. Multilocular cystic nephroma: MR imaging appearance with current techniques, including gadolinium enhancement. J Magn Reson Imaging. 1996;6:145–148
  80. Davis CJ, Barton JH, Sesterhenn IA, et al. Metanephric adenoma (Clinicopathological study of fifty patients). Am J Surg Pathol. 1995;19:1101–1114
  81. Tsuji M, Murakami Y, Kanayama H, et al. A case of renal metanephric adenoma: Histologic, immunohistochemical and cytogenetic analyses. Int J Urol. 1999;6:203–207
  82. Araki T, Hata H, Asakawa E, et al. MRI of metanephric adenoma. J Comput Assist Tomogr. 1998;22:87–90
  83. Imamoto T, Furuya Y, Ueda T, et al. Metanephric adenoma of the kidney. Int J Urol. 1999;6:200–202
  84. Jones EC, Pins M, Dickersin GR, et al. Metanephric adenoma of the kidney (A clinicopathological, immunohistochemical, flow cytometric, cytogenetic, and electron microscopic study of seven cases). Am J Surg Pathol. 1995;19:615–626

PII: S0887-2171(09)00027-4

doi: 10.1053/j.sult.2009.04.001

Seminars in Ultrasound, CT and MRI
Volume 30, Issue 4 , Pages 326-351 , August 2009

Article Tools

* Image Usage & Resolution